FAQ

We're not just another industry group—we're a collaborative force driving the future of pharmacogenomics in the UK. The UK-IPN unites commercial innovators with NHS, government, and regulatory bodies to break down barriers and embed PGx as standard care. We champion open dialogue, shared goals, transparency and integrity across diverse organisations.

• A strategic forum for shaping commercial pathways and commissioning processes for PGx services
• Engagement with NHS leaders to support national, regional, and local implementation
• Insight and involvement in key PGx initiatives, including regulatory innovation and work programmes
• A platform to raise visibility and credibility of PGx companies within UK healthcare
• Advisory access to BIVDA and ABPI, ensuring alignment with best practices and codes of conduct

The UK-IPGxN was born from a shared vision: to accelerate the adoption of pharmacogenomics across the UK healthcare system. Recognising the need for unified industry representation, the network was established to foster collaboration, influence policy, and support the NHS in delivering personalised medicine. Our founding principles—respect, transparency, and results—continue to guide every step.

We help by:

· Giving industry a unified voice in PGx development

· Supporting the NHS system with implementation strategies and awareness-building

· Identifying and solving barriers to PGx adoption using a collaborative approach

· Ensuring continuity and accountability through structured representation and shared responsibility

Because we're committed to impact. We don't just talk about innovation—we deliver it. Our members are actively shaping the future of PGx testing, contributing to strategic projects, and advocating for patient-centred care. We offer a seat at the table where decisions are made, and where commercial expertise meets public health ambition.